393 related articles for article (PubMed ID: 35004289)
1. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
Front Oncol; 2021; 11():771045. PubMed ID: 35004289
[TBL] [Abstract][Full Text] [Related]
2. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
Fulgenzi CAM; D'Alessio A; Airoldi C; Scotti L; Demirtas CO; Gennari A; Cortellini A; Pinato DJ
Eur J Cancer; 2022 Oct; 174():57-67. PubMed ID: 35970037
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis.
Long J; Chen B; Liu Z
Front Oncol; 2023; 13():1179431. PubMed ID: 37265792
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
6. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
Liu K; Zhu Y; Zhu H
Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J; Yang L; Wei S; Li J; Yi P
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16191-16201. PubMed ID: 37658861
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.
Vogel A; Finn RS; Blanchet Zumofen MH; Heuser C; Alvarez JS; Leibfried M; Mitchell CR; Batson S; Redhead G; Gaillard VE; Kudo M
Liver Cancer; 2023 Dec; 12(6):510-520. PubMed ID: 38058419
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials.
Hoang T; Sohn DK; Kim BC; Cha Y; Kim J
Front Oncol; 2021; 11():756214. PubMed ID: 35223449
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
Vogel A; Rimassa L; Sun HC; Abou-Alfa GK; El-Khoueiry A; Pinato DJ; Sanchez Alvarez J; Daigl M; Orfanos P; Leibfried M; Blanchet Zumofen MH; Gaillard VE; Merle P
Liver Cancer; 2021 Jun; 10(3):240-248. PubMed ID: 34239810
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
[No Abstract] [Full Text] [Related]
14. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.
Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H
Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533
[TBL] [Abstract][Full Text] [Related]
17. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
An J; Han S; Kim HI; Shim JH
Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lu J; Lin X; Teng H; Zheng Y
J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
Gong H; Ong SC; Li F; Weng Z; Zhao K; Jiang Z
Cost Eff Resour Alloc; 2023 Mar; 21(1):20. PubMed ID: 37004046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]